Transcript Slide presentation for Primary HPV consultation

National Cervical Screening Programme Changing the primary laboratory test
Public consultation
October 2015
Presentation overview
•
Success of the NCSP today
•
What is HPV?
•
HPV immunisation
•
Future directions – changing the primary screening test
•
Public consultation – what do you think?
NCSP Key Messages
•
Our NCSP is one of the most successful cervical screening programmes in
the world.
•
Cervical cancer is one of the most preventable cancers and screening
women every three years reduces the risk of developing it by up to 90
percent.
•
We are reducing the incidence and mortality rate of cervical cancer by
detecting and treating pre-cancerous squamous cell changes.
Reducing the incidence and mortality of cervical cancer
Source: Cervical Cancer : Symptoms, Stages and Treatment.
www.medicinenet.com493 × 335
What is HPV?
•
HPV is a common virus
•
Infects both men and women
•
It usually has no signs or symptoms and mostly goes away on its own
•
Some types cause cancers, including cervical cancer
Parkin, D. M and Gray, F. 2006. Chapter 2: The burden of HPV-related
cancers. Vaccine, 31(24)S3, 11-25
HPV immunisation
•
•
Immunisation and screening offer the most effective protection against
cervical cancer.
More Māori and Pacific women are HPV immunised than other ethnic
groups.
•
Protects against high-risk HPV (16 and18) that cause up to 70% of cervical
cancer. Also protects against genital warts (HPV 6 and 11). The vaccine
does not protect against all hrHPV types.
•
Immunised or not, women still need to participate in regular cervical
screening.
Future direction - Changing the test
Moving to HPV primary screening in NZ
•
•
WHO recommends hrHPV primary screening and many countries are
implementing HPV primary screening programmes
A woman still needs to have a smear
•
Less frequent screening: every 5 years instead of 3
•
Possible age range 25 – 69
•
Possibility of self-sampling for some women, could reduce barriers to
accessing screening
Potential benefits of HPV primary screening:
•
Fewer cervical cancer cases and deaths
•
Fewer smears throughout a woman’s life
•
Better detection of risk of precancerous cervical cell changes
•
Effective for HPV vaccinated, and those who are not
•
•
Test interpretation is less subjective
Opportunity for some women to do HPV self-sampling for women
•
New Zealand programme remains consistent with internationally recognised
best practice
Next steps
•
•
Public consultation during October 2015
What do you think? www.nsu.govt.nz
•
Nothing changes until 2018!
Questions?